Engineered exosomes for future gene-editing therapy.

Haoyu Guo, Xin Huang
{"title":"Engineered exosomes for future gene-editing therapy.","authors":"Haoyu Guo, Xin Huang","doi":"10.12336/biomatertransl.2022.04.003","DOIUrl":null,"url":null,"abstract":"The RNA-guided clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated nuclease protein 9 (Cas9)-based technology is an advanced and popular gene-editing technology, which has shown great potential in treating genetic disorders in both animal models and even in clinical trials.1, 2 Many transportation strategies are available for delivery of the CRISPR-Cas9 system, among which Cas9 ribonucleoprotein (RNP) delivery has some competitive advantages over other options, such as faster editing onset speed with a reduced immune response and lower off-target activity.3, 4 However, the low in vivo delivery efficiency and poor tissue specificity of RNP delivery have limited further clinical applications.5 Writing in Science Advances, Wan et al.6 reported a previously-unidentified genome editing delivery system, named exosomeRNP which transported RNPs within exosomes extracted from hepatic stellate cells via electroporation. The exosomeRNP exhibited effective intracellular and intercellular delivery and accumulation of RNPs to hepatocytes in vitro and in vivo, resulting in significant therapeutic effects in several hepatic diseases. The system was tested in mouse models of acute liver injury, chronic liver fibrosis, and hepatocellular carcinoma by targeting p53 upregulated modulator of apoptosis, cyclin-E1, and K(lysine) acetyltransferase-5, respectively, providing a potential strategy for high-efficiency, precise and tissue-specific gene editing in liver diseases.","PeriodicalId":58820,"journal":{"name":"Biomaterials Translational","volume":"3 4","pages":"240-242"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/10/bt-03-04-240.PMC9947735.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomaterials Translational","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12336/biomatertransl.2022.04.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

The RNA-guided clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated nuclease protein 9 (Cas9)-based technology is an advanced and popular gene-editing technology, which has shown great potential in treating genetic disorders in both animal models and even in clinical trials.1, 2 Many transportation strategies are available for delivery of the CRISPR-Cas9 system, among which Cas9 ribonucleoprotein (RNP) delivery has some competitive advantages over other options, such as faster editing onset speed with a reduced immune response and lower off-target activity.3, 4 However, the low in vivo delivery efficiency and poor tissue specificity of RNP delivery have limited further clinical applications.5 Writing in Science Advances, Wan et al.6 reported a previously-unidentified genome editing delivery system, named exosomeRNP which transported RNPs within exosomes extracted from hepatic stellate cells via electroporation. The exosomeRNP exhibited effective intracellular and intercellular delivery and accumulation of RNPs to hepatocytes in vitro and in vivo, resulting in significant therapeutic effects in several hepatic diseases. The system was tested in mouse models of acute liver injury, chronic liver fibrosis, and hepatocellular carcinoma by targeting p53 upregulated modulator of apoptosis, cyclin-E1, and K(lysine) acetyltransferase-5, respectively, providing a potential strategy for high-efficiency, precise and tissue-specific gene editing in liver diseases.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于未来基因编辑治疗的工程外泌体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.70
自引率
0.00%
发文量
9
期刊最新文献
"Yin-Yang philosophy" for the design of anticancer drug delivery nanoparticles. Abalone shell-derived Mg-doped mesoporous hydroxyapatite microsphere drug delivery system loaded with icariin for inducing apoptosis of osteosarcoma cells. Advanced nanoparticles in osteoarthritis treatment. Artificial intelligence-enabled studies on organoid and organoid extracellular vesicles. Corrigendum: Enhanced angiogenesis in porous poly(ε-caprolactone) scaffolds fortified with methacrylated hyaluronic acid hydrogel after subcutaneous transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1